Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
236.16
+10.67 (4.73%)
At close: May 31, 2024, 4:00 PM
220.00
-16.16 (-6.84%)
After-hours: May 31, 2024, 7:56 PM EDT
Company Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 376 |
| CEO | William J. Sibold |
Contact Details
Address: 200 Barr Harbor Drive, Suite 400 West Conshohocken, Pennsylvania 19428 United States | |
| Phone | 404-380-9263 |
| Website | madrigalpharma.com |
Stock Details
| Ticker Symbol | MDGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001157601 |
| CUSIP Number | 558868105 |
| ISIN Number | US5588681057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research and Development and Director |
| Brian J. Lynch J.D. | Senior Vice President and General Counsel |
| Alex G. Howarth | Executive Officer |
| William J. Sibold | Chief Executive Officer, President and Director |
| Mardi C. Dier | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Senior Vice President |
| Ronald Filippo | Chief Information Officer |
| Tina E. Ventura | Chief Investor Relations Officer |
| Dr. Kianoush Motesharei Ph.d. | Senior Vice President of Business and Corporate Development |
| Clint Wallace | Chief Human Resources Officer |
| Edward Chiang | Senior Vice President of Clinical and Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 144 | Filing |
| May 7, 2024 | 8-K | Current Report |
| May 7, 2024 | 424B3 | Prospectus |
| May 7, 2024 | 424B5 | Filing |
| May 7, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |